Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9573 posts found.

halaven

Eisai’s Halaven shown to restrict further cancer metastasis

December 11, 2015 Research and Development, Sales and Marketing Eisai, Halaven, Merck, keytruda

New data presented by Eisai supports the previously shown ability of Halaven (eribulin) to reverse epithelial-to-mesenchymal transition, the process by …
News
roche_scientists

Which are pharma’s most innovative companies?

December 11, 2015 Medical Communications, Research and Development GSK, Roche, research and development

It has been a record-breaking year for the pharmaceutical industry in terms of deals, but what about the underlying innovation …
Feature
AZ_scientist

AstraZeneca deal to delve into the secretome

December 11, 2015 Medical Communications, Research and Development AstraZeneca, MedImmune, biologics, secretome

MedImmune, the biologics research and development arm of pharma giant AstraZeneca, has signed a collaboration with Swedish universities and research …
News

NICE publishes draft guidance on two prostate cancer treatments

December 11, 2015 Medical Communications, Research and Development, Sales and Marketing Astellas, Janssen, NICE, Xtandi, Zytiga, prostate cancer

NICE has issued final draft guidance recommending Astellas Pharma’s Xtandi (enzalutamide) in prostate cancer prior to chemotherapy, but not Janssen’s …
News
xarelto

Regulators to probe Bayer’s Xarelto trial results

December 10, 2015 Medical Communications, Research and Development

Bayer’s blockbuster anticoagulant Xarelto is under scrutiny from regulators in Europe and the US, as they try to determine whether …
News
Novolog pen

Novo Nordisk files for new insulin approval

December 10, 2015 Manufacturing and Production, Research and Development, Sales and Marketing FDA, NDA, Novo Nordisk, NovoLog, diabetes, insulin aspart, new drug application

Novo Nordisk has submitted a New Drug Application (NDA) for faster-acting insulin aspart to the FDA. If successful, the Danish …
News
Merck researcher

Merck/Pfizer Alliance to collaborate on late-stage cancer trials

December 10, 2015 Research and Development Merck, Pfizer, avelumab, collaboration, gastric cancer, oncology, partnership, stomach cancer

Merck and Pfizer are partnering to run two Phase III trials of avelumab, an immuno-oncology treatment the companies hope to …
News
Guido Rasi

EMA sets out new five-year plan

December 9, 2015 Research and Development EMA, Guido Rasi

The European Medicines Agency’s (EMA) new executive director, Professor Guido Rasi, outlined his vision for his five-year mandate at the …
News
healthy-human-t-cell_credit_celgene-web

Researchers launch CAR-T cell therapy trial in head and neck cancer

December 9, 2015 Research and Development CAR-T, CAR-T therapy, Cancer, head and neck cancers, oncology R&D

A pioneering trial is beginning in London, where doctors are harnessing patients’ own immune systems to find a new effective …
News
Coartem dosing

Novartis reaches 300 million free antimalarial treatments

December 9, 2015 Manufacturing and Production, Research and Development Coartem, Novartis, antimalarial treatment, malaria, non-profit

Novartis has reached a delivery milestone of 300 million paediatric antimalarial treatments, having supplied its Coartem dispersible without profit to …
News
Collaboration

The age of collaboration: why pharma companies now have to work together

December 9, 2015 Research and Development R&D, co-operation, collaboration, pharma

It seems 2015 may be remembered as the year of the mega merger; the year when all records were broken …
Feature
Gilead sign

Gilead awaits EU decision on hep C combo treatment

December 8, 2015 Research and Development EMA, Gilead, SOF/VEL, accelerated assessment, hepatitis C, sovaldi, velpatasvir

The EMA has granted Gilead Sciences an accelerated assessment for its application for a new Sovaldi combination treatment.The combination contains …
News
Red blood cells

ASH 2015 roundup: Amgen, MorphoSys, Novartis and Roche present new trial data

December 8, 2015 Research and Development Amgen, Cancer, Novartis, Roche, ash, morphosys, oncology

Amgen Amgen presented data from three Phase II trials evaluating Blincyto (blinatumomab) in acute lymphoblastic leukemia (ALL)- a rare and …
News
janssen_latest_logo_on_sign_closer

Strong cancer trial data for Janssen at ASH 2015

December 8, 2015 Research and Development Cancer, Janssen, darzalex, imbruvica, oncology

Janssen presented new cancer trial data at the 57th Annual American Society of Haematology (ASH) meeting Orlando, Florida – with …
News
Ninlaro

Takeda’s Ninlaro extends myeloma survival in trial

December 7, 2015 Manufacturing and Production, Research and Development Ninlaro, Takeda, ash, ixazomib, multiple myeloma

Takeda has presented trial data showing that treatment with its oral proteasome inhibitor Ninlaro extended progression free survival by 35% …
News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025